TP53 and triple-negative breast carcinoma: To examine the therapeutic relevance of targeting SESTRIN 2 we examined the ability of a panel of commonly used chemotherapeutics to induce SESTRIN 2 expression in MCF7 cells and the P53 null triple negative breast cancer cell line HCC1806.